Can NF-κB be a target for novel and efficient anti-cancer agents?

Biochemical Pharmacology

Volumn 72, Issue 9 SPEC. ISS., 2006, Pages 1054-1068

  Olivier, Sabine ^a   Robe, Pierre ^a   Bours, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Apoptosis; Cancer; Chemotherapy; IKK; NF B; Proteasome

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AS 602868; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CIGLITAZONE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DICLOFENAC; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GANCICLOVIR; GLUCOCORTICOID; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MELPHALAN; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PREDNISOLONE; RALOXIFENE; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULINDAC; TAMOXIFEN; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNBS 1450; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; BORONIC ACID DERIVATIVE; I KAPPA B KINASE; PROTEASOME; PYRAZINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL CYCLE REGULATION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; ENTERITIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; GENE THERAPY; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKEMIA; LIVER CANCER; LUNG CALCIFICATION; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STOMACH CANCER; DRUG ANTAGONISM; METABOLISM; PHOSPHORYLATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; GLUCOCORTICOIDS; HUMANS; I-KAPPA B KINASE; MULTIPLE MYELOMA; NF-KAPPA B; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 33749051213     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.07.023     Document Type: Review

References (209)

1. Rayet B., and Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
2. Pikarsky E., and Ben-Neriah Y. NF-kappaB inhibition: a double-edged sword in cancer?. Eur J Cancer 42 (2006) 779-784
3. Kim H.J., Hawke N., and Baldwin A.S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 13 (2006) 738-747
4. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 (2002) 301-310
5. Loercher A., Lee T.L., Ricker J.L., Howard A., Geoghegen J., Chen Z., et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64 (2004) 6511-6523
6. Robe P.A., Bentires-Alj M., Bonif M., Rogister B., Deprez M., Haddada H., et al. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10 (2004) 5595-5603
7. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100 (1997) 2952-2960
8. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
9. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
10. Frelin C., Imbert V., Griessinger E., Peyron A.C., Rochet N., Philip P., et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105 (2005) 804-811
11. Wang C.Y., Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5 (1999) 412-417
12. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274 (1996) 784-787
13. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 (2003) 90-97
14. Ashikawa K., Shishodia S., Fokt I., Priebe W., and Aggarwal B.B. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol 67 (2004) 353-364
15. Campbell K.J., Rocha S., and Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 13 (2004) 853-865
16. Dajee M., Lazarov M., Zhang J.Y., Cai T., Green C.L., Russell A.J., et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421 (2003) 639-643
17. Ho W.C., Dickson K.M., and Barker P.A. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res 65 (2005) 4273-4281
18. Ryan K.M., Ernst M.K., Rice N.R., and Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404 (2000) 892-897
19. Zhang J.Y., Green C.L., Tao S., and Khavari P.A. NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev 18 (2004) 17-22
20. Stark L.A., Din F.V., Zwacka R.M., and Dunlop M.G. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. Faseb J 15 (2001) 1273-1275
21. Chan A.T., Giovannucci E.L., Schernhammer E.S., Colditz G.A., Hunter D.J., Willett W.C., et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 140 (2004) 157-166
22. Collet J.P., Sharpe C., Belzile E., Boivin J.F., Hanley J., and Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81 (1999) 62-68
23. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348 (2003) 883-890
24. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
25. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
26. Yamamoto Y., Yin M.J., Lin K.M., and Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274 (1999) 27307-27314
27. Takada Y., Bhardwaj A., Potdar P., and Aggarwal B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23 (2004) 9247-9258
28. Palayoor S.T., Youmell M.Y., Calderwood S.K., Coleman C.N., and Price B.D. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18 (1999) 7389-7394
29. Stark L.A., and Dunlop M.G. Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Mol Cell Biol 25 (2005) 5985-6004
30. Cho M., Gwak J., Park S., Won J., Kim D.E., Yea S.S., et al. Diclofenac attenuates Wnt/beta-catenin signaling in colon cancer cells by activation of NF-kappaB. FEBS Lett 579 (2005) 4213-4218
31. Chang E.T., Zheng T., Weir E.G., Borowitz M., Mann R.B., Spiegelman D., et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 96 (2004) 305-315
32. Dasgupta K., Di Cesar D., Ghosn J., Rajan R., Mahmud S., and Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12 (2006) 130-135
33. Liu J.F., Jamieson G.G., Drew P.A., Zhu G.J., Zhang S.W., Zhu T.N., et al. Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2. ANZ J Surg 75 (2005) 1011-1016
34. Mahmud S.M., Tanguay S., Begin L.R., Franco E.L., and Aprikian A.G. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 15 (2006) 158-164
35. Moysich K.B., Menezes R.J., Ronsani A., Swede H., Reid M.E., Cummings K.M., et al. Regular aspirin use and lung cancer risk. BMC Cancer 2 (2002) 31
36. Shishodia S., Koul D., and Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173 (2004) 2011-2022
37. Vaughan T.L., Dong L.M., Blount P.L., Ayub K., Odze R.D., Sanchez C.A., et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6 (2005) 945-952
38. Tanigawara Y., Kita T., Aoyama N., Gobara M., Komada F., Sakai T., et al. N-Acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull 25 (2002) 1058-1062
39. Kita T., Sakaeda T., Adachi S., Sakai T., Aoyama N., Hatanaka H., et al. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol Pharm Bull 24 (2001) 1176-1180
40. Wahl C., Liptay S., Adler G., and Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101 (1998) 1163-1174
41. Weber C.K., Liptay S., Wirth T., Adler G., and Schmid R.M. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119 (2000) 1209-1218
42. Egan L.J., Mays D.C., Huntoon C.J., Bell M.P., Pike M.G., Sandborn W.J., et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 274 (1999) 26448-26453
43. Chung W.J., Lyons S.A., Nelson G.M., Hamza H., Gladson C.L., Gillespie G.Y., et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25 (2005) 7101-7110
44. Gout P.W., Buckley A.R., Simms C.R., and Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. Leukemia 15 (2001) 1633-1640
45. Narang V.S., Pauletti G.M., Gout P.W., Buckley D.J., and Buckley A.R. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res 23 (2003) 4571-4579
46. Awasthi S., Sharma R., Singhal S.S., Herzog N.K., Chaubey M., and Awasthi Y.C. Modulation of cisplatin cytotoxicity by sulphasalazine. Br J Cancer 70 (1994) 190-194
47. Ryu B.R., Lee Y.A., Won S.J., Noh J.H., Chang S.Y., Chung J.M., et al. The novel neuroprotective action of sulfasalazine through blockade of NMDA receptors. J Pharmacol Exp Ther 305 (2003) 48-56
48. Cronstein B.N., Montesinos M.C., and Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci USA 96 (1999) 6377-6381
49. van der Heijden J., de Jong M.C., Dijkmans B.A., Lems W.F., Oerlemans R., Kathmann I., et al. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 63 (2004) 138-143
50. Ryan B.M., Russel M.G., Langholz E., and Stockbrugger R.W. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol 98 (2003) 1682-1687
51. Program N.T. NTP toxicology and carcinogenesis studies of salicylazosulfapyridine (CAS No. 599-79-1) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 457 (1997) 1-327
52. Espin Jaime M.T., Moran Penco J.M., Garcia Agundez J.A., Caballero Loscos M.J., Sanjuan Rodriguez S., Botello Martinez F., et al. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine. Br J Urol 80 (1997) 151-152
53. Gout P.W., Simms C.R., and Robertson M.C. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs 14 (2003) 21-29
54. Habens F., Srinivasan N., Oakley F., Mann D.A., Ganesan A., and Packham G. Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis 10 (2005) 481-491
55. Liptay S., Fulda S., Schanbacher M., Bourteele S., Ferri K.F., Kroemer G., et al. Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br J Pharmacol 137 (2002) 608-620
56. Salh B., Assi K., Huang S., O'Brien L., Steinbrecher U., and Gomez-Munoz A. Dissociated ROS production and ceramide generation in sulfasalazine-induced cell death in Raw 264, 7 cells. J Leukoc Biol 72 (2002) 790-799
57. Muerkoster S., Arlt A., Witt M., Gehrz A., Haye S., March C., et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 104 (2003) 469-476
58. Arlt A., Vorndamm J., Breitenbroich M., Folsch U.R., Kalthoff H., Schmidt W.E., et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20 (2001) 859-868
59. Hermisson M., and Weller M. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells. Cell Death Differ 10 (2003) 1078-1089
60. Moriuchi S., Glorioso J.C., Maruno M., Izumoto S., Wolfe D., Huang S., et al. Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther 12 (2005) 487-496
61. Gupta V., Jani J.P., Jacobs S., Levitt M., Fields L., Awasthi S., et al. Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. Cancer Chemother Pharmacol 36 (1995) 13-19
62. Nagai S., Washiyama K., Kurimoto M., Takaku A., Endo S., and Kumanishi T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96 (2002) 909-917
63. Robe P.A., Martin D., Albert A., Deprez M., Chariot A., and Bours V. A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer 6 (2006) 29
64. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24 (2003) 488-522
65. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
66. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
67. Brostjan C., Anrather J., Csizmadia V., Stroka D., Soares M., Bach F.H., et al. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem 271 (1996) 19612-19616
68. De Bosscher K., Schmitz M.L., Vanden Berghe W., Plaisance S., Fiers W., and Haegeman G. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 94 (1997) 13504-13509
69. Ray A., and Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 91 (1994) 752-756
70. Liden J., Rafter I., Truss M., Gustafsson J.A., and Okret S. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. Biochem Biophys Res Commun 273 (2000) 1008-1014
71. Kagoshima M., Wilcke T., Ito K., Tsaprouni L., Barnes P.J., Punchard N., et al. Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. Eur J Pharmacol 429 (2001) 327-334
72. Nissen R.M., and Yamamoto K.R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14 (2000) 2314-2329
73. Kalaitzidis D., and Gilmore T.D. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 16 (2005) 46-52
74. Olivier S., Close P., Castermans E., de Leval L., Tabruyn S., Chariot A., et al. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-{kappa}B inhibition and gene expression signature. Mol Pharmacol 69 (2006) 1615-1623
75. Decaudin D., Etienne M.C., De Cremoux P., Maciorowski Z., Vantelon J.M., Voog E., et al. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma. J Natl Cancer Inst 96 (2004) 636-637
76. Fassas A.B., Rapoport A.P., Bolanos-Meade J., Shanholtz C., Cottler-Fox M., and Tricot G. Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leuk Lymphoma 42 (2001) 1323-1328
77. Ray D.M., Akbiyik F., Bernstein S.H., and Phipps R.P. CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism. J Immunol 174 (2005) 4060-4069
78. Chen F., Wang M., O'Connor J.P., He M., Tripathi T., and Harrison L.E. Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J Cell Biochem 90 (2003) 732-744
79. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104 (1999) 383-389
80. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 (2000) 103-108
81. Keshamouni V.G., Arenberg D.A., Reddy R.C., Newstead M.J., Anthwal S., and Standiford T.J. PPAR-gamma activation inhibits angiogenesis by blocking ELR + CXC chemokine production in non-small cell lung cancer. Neoplasia 7 (2005) 294-301
82. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
83. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin Jr. A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276 (2001) 22382-22387
84. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99 (2002) 4525-4530
85. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 (2001) 1950-1961
86. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96 (2000) 2943-2950
87. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
88. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
89. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4 (2004) 314-322
90. Jundt F., Raetzel N., Muller C., Calkhoven C.F., Kley K., Mathas S., et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 106 (2005) 1801-1807
91. Chen J., and Fang Y. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 64 (2002) 1071-1077
92. Romano M.F., Avellino R., Petrella A., Bisogni R., Romano S., and Venuta S. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 40 (2004) 2829-2836
93. Ueno S., Aoki D., Kubo F., Hiwatashi K., Matsushita K., Oyama T., et al. Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by diminishing oxidative stress in a rat model of hepatocellular carcinoma. Clin Cancer Res 11 (2005) 5645-5650
94. Ichiyama T., Nishikawa M., Yoshitomi T., Hasegawa S., Matsubara T., Hayashi T., et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45 (2001) 44-47
95. Manna S.K., Sah N.K., Newman R.A., Cisneros A., and Aggarwal B.B. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res 60 (2000) 3838-3847
96. Yang Q., Huang W., Jozwik C., Lin Y., Glasman M., Caohuy H., et al. Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc Natl Acad Sci USA 102 (2005) 9631-9636
97. Sreenivasan Y., Sarkar A., and Manna S.K. Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 66 (2003) 2223-2239
98. Mijatovic T., Op De Beeck A., Van Quaquebeke E., Dewelle J., Darro F., de Launoit Y., et al. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther 5 (2006) 391-399
99. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3 (2004) 17-26
100. Nakanishi C., and Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5 (2005) 297-309
101. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 8 (2002) S49-S54
102. Kisselev A.F., Garcia-Calvo M., Overkleeft H.S., Peterson E., Pennington M.W., Ploegh H.L., et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 278 (2003) 35869-35877
103. Dick T.P., Nussbaum A.K., Deeg M., Heinemeyer W., Groll M., Schirle M., et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem 273 (1998) 25637-25646
104. Arora S., Yang J.M., and Hait W.N. Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res 65 (2005) 3806-3810
105. Blagosklonny M.V., Wu G.S., Omura S., and el-Deiry W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 227 (1996) 564-569
106. Breitschopf K., Zeiher A.M., and Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 275 (2000) 21648-21652
107. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 21 (2006) 307-315
108. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279 (2004) 5405-5412
109. Hu X., Bryington M., Fisher A.B., Liang X., Zhang X., Cui D., et al. Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem 277 (2002) 16528-16537
110. Kitagawa H., Tani E., Ikemoto H., Ozaki I., Nakano A., and Omura S. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 443 (1999) 181-186
111. Ougolkov A., Zhang B., Yamashita K., Bilim V., Mai M., Fuchs S.Y., et al. Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer. J Natl Cancer Inst 96 (2004) 1161-1170
112. Podust V.N., Brownell J.E., Gladysheva T.B., Luo R.S., Wang C., Coggins M.B., et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA 97 (2000) 4579-4584
113. Welcker M., Orian A., Grim J.E., Eisenman R.N., and Clurman B.E. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol 14 (2004) 1852-1857
114. Yamasaki L., and Pagano M. Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 16 (2004) 623-628
115. Zhu H., Zhang L., Dong F., Guo W., Wu S., Teraishi F., et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341 Velcade) and other proteasome inhibitors. Oncogene 24 (2005) 4993-4999
116. Roccaro A.M., Hideshima T., Raje N., Kumar S., Ishitsuka K., Yasui H., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66 (2006) 184-191
117. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., and McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2 (2003) 835-843
118. Park B.K., Zeng X., and Glazer R.I. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 61 (2001) 7647-7653
119. Podar K., Shringarpure R., Tai Y.T., Simoncini M., Sattler M., Ishitsuka K., et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 64 (2004) 7500-7506
120. Hong X., Lei L., and Glas R. Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis. J Exp Med 197 (2003) 1731-1743
121. Li M., Wang Y., Hung M.C., and Kannan P. Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer. Int J Cancer 118 (2006) 802-811
122. Chiarle R., Budel L.M., Skolnik J., Frizzera G., Chilosi M., Corato A., et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95 (2000) 619-626
123. Barnes C.J., Li F., Talukder A.H., and Kumar R. Growth factor regulation of a 26S proteasomal subunit in breast cancer. Clin Cancer Res 11 (2005) 2868-2874
124. Dressman M.A., Baras A., Malinowski R., Alvis L.B., Kwon I., Walz T.M., et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 63 (2003) 2194-2199
125. Thompson H.G., Harris J.W., Wold B.J., and Lin F. Brody JP. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 22 (2003) 2322-2333
126. Masdehors P., Omura S., Merle-Beral H., Mentz F., Cosset J.M., Dumont J., et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 105 (1999) 752-757
127. Mason R.W. Characterization of the active site of human multicatalytic proteinase. Biochem J 265 (1990) 479-484
128. Wilk S., and Figueiredo-Pereira M.E. Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enzyme Protein 47 (1993) 306-313
129. Craiu A., Gaczynska M., Akopian T., Gramm C.F., Fenteany G., Goldberg A.L., et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272 (1997) 13437-13445
130. Omura S., Matsuzaki K., Fujimoto T., Kosuge K., Furuya T., Fujita S., et al. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot (Tokyo) 44 (1991) 117-118
131. Adams G.M., Crotchett B., Slaughter C.A., DeMartino G.N., and Gogol E.P. Formation of proteasome-PA700 complexes directly correlates with activation of peptidase activity. Biochemistry 37 (1998) 12927-12932
132. Iqbal M., Chatterjee S., Kauer J.C., Das M., Messina P., Freed B., et al. Potent inhibitors of proteasome. J Med Chem 38 (1995) 2276-2277
133. Gaczynska M., Osmulski P.A., Gao Y., Post M.J., and Simons M. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42 (2003) 8663-8670
134. Kisselev A.F., and Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8 (2001) 739-758
135. Chauhan D., Li G., Podar K., Hideshima T., Neri P., He D., et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 65 (2005) 8350-8358
136. Schwartz R., and Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 18 (2004) 14-21
137. Lightcap E.S., McCormack T.A., Pien C.S., Chau V., Adams J., and Elliott P.J. Proteasome inhibition measurements: clinical application. Clin Chem 46 (2000) 673-683
138. Lun M., Zhang P.L., Siegelmann-Danieli N., Blasick T.M., and Brown R.E. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines. Ann Clin Lab Sci 35 (2005) 15-24
139. Adachi M., Zhang Y., Zhao X., Minami T., Kawamura R., Hinoda Y., et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 10 (2004) 3853-3862
140. Bunn Jr. P.A. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res 10 (2004) 4263s-4265s
141. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl Bancroft C., Sausville E., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7 (2001) 1419-1428
142. Boccadoro M., Morgan G., and Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5 (2005) 18
143. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner Jr. K., et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66 (2006) 3773-3781
144. Yin D., Zhou H., Kumagai T., Liu G., Ong J.M., Black K.L., et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24 (2005) 344-354
145. Michaelis M., Fichtner I., Behrens D., Haider W., Rothweiler F., Mack A., et al. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 28 (2006) 439-446
146. Zheng B., Georgakis G.V., Li Y., Bharti A., McConkey D., Aggarwal B.B., et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10 (2004) 3207-3215
147. Dai Y., Rahmani M., and Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22 (2003) 7108-7122
148. Satou Y., Nosaka K., Koya Y., Yasunaga J.I., Toyokuni S., and Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18 (2004) 1357-1363
149. Van Waes C., Chang A.A., Lebowitz P.F., Druzgal C.H., Chen Z., Elsayed Y.A., et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) 1400-1412
150. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 (2002) 16639-16647
151. Hideshima T., Mitsiades C., Akiyama M., Hayashi T., Chauhan D., Richardson P., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-1534
152. Pajonk F., Pajonk K., and McBride W.H. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47 (2000) 1025-1032
153. Mackay H., Hedley D., Major P., Townsley C., Mackenzie M., Vincent M., et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11 (2005) 5526-5533
154. Dolcet X., Llobet D., Encinas M., Pallares J., Cabero A., Schoenenberger J.A., et al. Proteasome inhibitors induce death but activate NF-kappa B on endometrial carcinoma cell lines and primary culture explants. J Biol Chem (2006)
155. Vodanovic-Jankovic S., Hari P., Jacobs P., Komorowski R., and Drobyski W.R. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 107 (2006) 827-834
156. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 (2001) 3071-3076
157. Ma M.H., Yang H.H., Parker K., Manyak S., Friedman J.M., Altamirano C., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9 (2003) 1136-1144
158. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
159. Nencioni A., Wille L., Dal Bello G., Boy D., Cirmena G., Wesselborg S., et al. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res 11 (2005) 4259-4265
160. Yanamandra N., Colaco N.M., Parquet N.A., Buzzeo R.W., Boulware D., Wright G., et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 12 (2006) 591-599
161. Dou Q.P., McGuire T.F., Peng Y., and An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 289 (1999) 781-790
162. Chauhan D., Li G., Shringarpure R., Podar K., Ohtake Y., Hideshima T., et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63 (2003) 6174-6177
163. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
164. Dispenzieri A. Bortezomib for myeloma-much ado about something. N Engl J Med 352 (2005) 2546-2548
165. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
166. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D.H., et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 106 (2006) 1316-1319
167. Berenson J.R., Yang H.H., Sadler K., Jarutirasarn S.G., Vescio R.A., Mapes R., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24 (2006) 937-944
168. Ciolli S., Leoni F., Gigli F., Rigacci L., and Bosi A. Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 47 (2006) 171-173
169. Oakervee H.E., Popat R., Curry N., Smith P., Morris C., Drake M., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129 (2005) 755-762
170. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 (2002) 2505-2511
171. Scagliotti G. Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol (2006)
172. Goy A., Younes A., McLaughlin P., Pro B., Romaguera J.E., Hagemeister F., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 667-675
173. Alberts S.R., Foster N.R., Morton R.F., Kugler J., Schaefer P., Wiesenfeld M., et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 16 (2005) 1654-1661
174. Davis N.B., Taber D.A., Ansari R.H., Ryan C.W., George C., Vokes E.E., et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22 (2004) 115-119
175. Markovic S.N., Geyer S.M., Dawkins F., Sharfman W., Albertini M., Maples W., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 (2005) 2584-2589
176. Jeon K.I., Byun M.S., and Jue D.M. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med 35 (2003) 61-66
177. Mathas S., Lietz A., Janz M., Hinz M., Jundt F., Scheidereit C., et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102 (2003) 1028-1034
178. Kim K.B., Bedikian A.Y., Camacho L.H., Papadopoulos N.E., and McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104 (2005) 1687-1692
179. Mathews V., George B., Lakshmi K.M., Viswabandya A., Bajel A., Balasubramanian P., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107 (2006) 2627-2632
180. Murgo A.J. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 6 Suppl 2 (2001) 22-28
181. Woo S.Y., Lee M.Y., Jung Y.J., Yoo E.S., Seoh J.Y., Shin H.Y., et al. Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol 23 (2006) 231-243
182. Kim I.S., Jin J.Y., Lee I.H., and Park S.J. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol 142 (2004) 749-755
183. Bernier M., Kwon Y.K., Pandey S.K., Zhu T.N., Zhao R.J., Maciuk A., et al. Binding of manumycin A inhibits IkappaB kinase beta activity. J Biol Chem 281 (2006) 2551-2561
184. Liang M.C., Bardhan S., Li C., Pace E.A., Porco Jr. J.A., and Gilmore T.D. Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinase. Mol Pharmacol 64 (2003) 123-131
185. Wang W., and Macaulay R.J. Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A. Int J Cancer 82 (1999) 430-434
186. Zhou J.M., Zhu X.F., Pan Q.C., Liao D.F., Li Z.M., and Liu Z.C. Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells. Int J Mol Med 12 (2003) 955-959
187. May M.J., D'Acquisto F., Madge L.A., Glockner J., Pober J.S., and Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289 (2000) 1550-1554
188. Biswas D.K., Shi Q., Baily S., Strickland I., Ghosh S., Pardee A.B., et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101 (2004) 10137-10142
189. di Meglio P., Ianaro A., and Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 52 (2005) 951-958
190. Tas S.W., Vervoordeldonk M.J., Hajji N., May M.J., Ghosh S., and Tak P.P. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 8 (2006) R86
191. Castro A.C., Dang L.C., Soucy F., Grenier L., Mazdiyasni H., Hottelet M., et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 13 (2003) 2419-2422
192. Burke J.R., Pattoli M.A., Gregor K.R., Brassil P.J., MacMaster J.F., McIntyre K.W., et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 278 (2003) 1450-1456
193. Yang J., Amiri K.I., Burke J.R., Schmid J.A., and Richmond A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12 (2006) 950-960
194. Johanson V., Arvidsson Y., Kolby L., Bernhardt P., Sward C., Nilsson O., et al. Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice. Neuroendocrinology 82 (2006) 171-176
195. Ekelund S., Sjoholm A., Nygren P., Binderup L., and Larsson R. Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone). Eur J Pharmacol 418 (2001) 39-45
196. Hjarnaa P.J., Jonsson E., Latini S., Dhar S., Larsson R., Bramm E., et al. CHS, 828 a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 59 (1999) 5751-5757
197. Ravaud A., Cerny T., Terret C., Wanders J., Bui B.N., Hess D., et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 41 (2005) 702-707
198. Murata T., Shimada M., Sakakibara S., Yoshino T., Masuda T., Shintani T., et al. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3. Orally active anti-inflammatory agents. Bioorg Med Chem Lett 14 (2004) 4019-4022
199. Sanda T., Iida S., Ogura H., Asamitsu K., Murata T., Bacon K.B., et al. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res 11 (2005) 1974-1982
200. Sanda T., Asamitsu K., Ogura H., Iida S., Utsunomiya A., Ueda R., et al. Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor. Leukemia 20 (2006) 590-598
201. Frelin C., Imbert V., Griessinger E., Loubat A., Dreano M., and Peyron J.F. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells. Oncogene 22 (2003) 8187-8194
202. Kawamura I., Morishita R., Tomita N., Lacey E., Aketa M., Tsujimoto S., et al. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 6 (1999) 91-97
203. Kawamura I., Morishita R., Tsujimoto S., Manda T., Tomoi M., Tomita N., et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 8 (2001) 905-912
204. Guo J., Verma U.N., Gaynor R.B., Frenkel E.P., and Becerra C.R. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 10 (2004) 3333-3341
205. Pasparakis M., Schmidt-Supprian M., and Rajewsky K. IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med 196 (2002) 743-752
206. Siebenlist U., Brown K., and Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 5 (2005) 435-445
207. Kashatus D., Cogswell P., and Baldwin A.S. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 20 (2006) 225-235
208. Tergaonkar V., Pando M., Vafa O., and Wahl G. Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1 (2002) 493-503
209. Bentires-Alj M., Hellin A.C., Ameyar M., Chouaib S., Merville M.P., and Bours V. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 59 (1999) 811-815